DK1623703T3 - Controlled release hydrocodone formulations - Google Patents

Controlled release hydrocodone formulations

Info

Publication number
DK1623703T3
DK1623703T3 DK05019453.9T DK05019453T DK1623703T3 DK 1623703 T3 DK1623703 T3 DK 1623703T3 DK 05019453 T DK05019453 T DK 05019453T DK 1623703 T3 DK1623703 T3 DK 1623703T3
Authority
DK
Denmark
Prior art keywords
dosage form
controlled release
hydrocodone
release hydrocodone
hydrocodone formulations
Prior art date
Application number
DK05019453.9T
Other languages
Danish (da)
Inventor
Benjamin Oshlack
Hua-Pin Huang
Alfred P Tonelli
John Masselink
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22586071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1623703(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of DK1623703T3 publication Critical patent/DK1623703T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Abstract

A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C 12 /C max ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
DK05019453.9T 1999-10-29 2000-10-30 Controlled release hydrocodone formulations DK1623703T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16254199P 1999-10-29 1999-10-29
EP00976730A EP1227798A4 (en) 1999-10-29 2000-10-30 Controlled release hydrocodone formulations

Publications (1)

Publication Number Publication Date
DK1623703T3 true DK1623703T3 (en) 2011-11-28

Family

ID=22586071

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05019453.9T DK1623703T3 (en) 1999-10-29 2000-10-30 Controlled release hydrocodone formulations

Country Status (21)

Country Link
US (12) US7943174B2 (en)
EP (5) EP2269587A1 (en)
JP (6) JP4806507B2 (en)
KR (8) KR101197919B1 (en)
CN (3) CN107213128A (en)
AT (1) ATE526950T1 (en)
AU (2) AU764453B2 (en)
BR (1) BRPI0015284B8 (en)
CA (1) CA2389235C (en)
CY (1) CY1112260T1 (en)
DK (1) DK1623703T3 (en)
ES (1) ES2374717T3 (en)
HK (2) HK1054698A1 (en)
HU (1) HU230828B1 (en)
IL (4) IL149352A0 (en)
MX (1) MXPA02004293A (en)
NO (1) NO333380B1 (en)
NZ (1) NZ529928A (en)
PT (1) PT1623703E (en)
RU (1) RU2230556C2 (en)
WO (1) WO2001032148A1 (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1050306A (en) * 1996-07-31 1998-02-20 Toyota Autom Loom Works Ltd Manufacture of hydrogen storage alloy electrode
US20080102121A1 (en) * 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
EP2269587A1 (en) 1999-10-29 2011-01-05 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU2738302A (en) 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
CA2449519A1 (en) * 2001-06-08 2002-12-19 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
CA2452874A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
PE20030527A1 (en) * 2001-10-24 2003-07-26 Gruenenthal Chemie DELAYED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND ORAL TABLETS CONTAINING IT
SK286107B6 (en) * 2002-04-12 2008-03-05 Zentiva, A. S. Analgesically active peroral therapeutic composition with controlled release of an opioid active substance and method for the preparation thereof
CA2499994C (en) * 2002-09-23 2012-07-10 Verion, Inc. Abuse-resistant pharmaceutical compositions
ATE495732T1 (en) 2003-03-26 2011-02-15 Egalet As CONTROLLED RELEASE MORPHINE SYSTEM
CA2519556C (en) * 2003-04-21 2011-01-18 Benjamin Oshlack Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
EP3326617A1 (en) 2004-06-12 2018-05-30 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
EP1786404A2 (en) * 2004-09-01 2007-05-23 Euro-Celtique S.A. Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
SG157415A1 (en) * 2004-11-23 2009-12-29 Adamas Pharmaceuticals Inc Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
ATE481096T1 (en) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING CNS DISEASES
JP2009541360A (en) * 2006-06-23 2009-11-26 エラン・ファルマ・インターナショナル・リミテッド Composition comprising nanoparticulate meloxicam and controlled release hydrocodone
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
PL2124556T3 (en) 2006-10-09 2015-02-27 Charleston Laboratories Inc Pharmaceutical compositions
GB0625646D0 (en) * 2006-12-21 2007-01-31 Jagotec Ag Improvements in or relating to organic compounds
JP2010521494A (en) * 2007-03-16 2010-06-24 エラン・ファルマ・インターナショナル・リミテッド Combination of narcotic and non-narcotic analgesics
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20080318994A1 (en) 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
CN101917977B (en) * 2007-07-20 2013-05-29 艾博特股份有限两合公司 Formulations of nonopioid and confined opioid analgesics
GB0714790D0 (en) * 2007-07-30 2007-09-12 Jagotec Ag Improvements in or relating to organic compounds
US8124126B2 (en) 2008-01-09 2012-02-28 Charleston Laboratories, Inc. Pharmaceutical compositions
JP2011511782A (en) 2008-02-12 2011-04-14 アボット・ラボラトリーズ Extended release hydrocodone acetaminophen and related methods and uses
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
EP2262484B1 (en) 2008-03-11 2013-01-23 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
ES2536736T3 (en) * 2008-09-04 2015-05-28 Farnam Companies, Inc. Chewable sustained release formulations
BRPI0923836A2 (en) 2008-12-31 2015-07-21 Upsher Smith Lab Inc Opioid-containing oral pharmaceutical compositions and methods
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP3045043B1 (en) * 2009-02-26 2020-04-29 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US9023390B2 (en) 2009-09-17 2015-05-05 Upsher-Smith Laboratories, Inc. Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
EP2506709B2 (en) 2009-12-02 2019-10-09 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20130209560A1 (en) * 2010-02-24 2013-08-15 Cima Labs Inc. Abuse-resistant formulations
EP2371356B1 (en) * 2010-03-12 2012-12-19 Phoeme GmbH Multi-particle pharmaceutical formulation for colon absorption
EP2826468A1 (en) 2010-12-22 2015-01-21 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
CN103327969A (en) 2010-12-23 2013-09-25 普渡制药公司 Tamper resistant solid oral dosage forms
JP6016810B2 (en) * 2011-01-11 2016-10-26 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. Composition comprising an enzyme-cleavable oxycodone prodrug
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
WO2012166998A1 (en) * 2011-05-31 2012-12-06 QRxPharma Ltd. Compositions for sequential administration of opioid receptor agonists
RU2573388C2 (en) 2011-10-26 2016-01-20 Кемфарм Инк. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods for producing and using them
TW201811332A (en) 2012-04-17 2018-04-01 美商普渡製藥有限合夥事業 Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
KR101840526B1 (en) 2013-02-05 2018-03-20 퍼듀 퍼머 엘피 Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9510976B2 (en) 2014-04-29 2016-12-06 Abbott Cardiovascular Systems Inc. Devices and methods for treatment of the Eustachian tube and sinus cavity
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
GB201420311D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Pharmaceutical processing
GB201420306D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Compositions
GB201420300D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Tablet
KR20170094251A (en) 2014-12-02 2017-08-17 켐팜 인코포레이티드 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods and making and use thereof
EP3324975B1 (en) 2015-07-22 2022-05-18 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
JP2019507181A (en) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド Pharmaceutical composition
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
WO2018071381A1 (en) 2016-10-10 2018-04-19 Rhodes Pharmaceuticals L.P. Pharmaceutical resinate compositions and methods of making and using thereof
EP3554548A4 (en) 2016-12-19 2020-08-19 The Regents of The University of California Noncrushable pill formulatiions
WO2018119033A1 (en) * 2016-12-20 2018-06-28 Cima Labs Inc. Abuse-resistant and abuse-deterrent dosage forms
JP7132924B2 (en) * 2016-12-22 2022-09-07 ゼナメッド コーポレーション Droxidopa compositions and methods
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10759865B2 (en) 2017-08-22 2020-09-01 Eyal Levit Treatment of diabetes mellitus
US11690840B2 (en) * 2017-10-09 2023-07-04 Rhodes Pharmaceuticals L.P. Pharmaceutical resinate compositions and methods of making and using thereof
EP4176724A1 (en) 2021-11-09 2023-05-10 Universität Hohenheim Use of an oleogel as a layer or coating

Family Cites Families (391)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US834985A (en) * 1905-09-28 1906-11-06 Simon Lake Sighting instrument.
US2652098A (en) 1951-08-25 1953-09-15 American Seating Co Folding chair
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
GB1082206A (en) 1963-07-02 1967-09-06 Applic Chimiques D Etudes & De Improved antibiotic medicine
US4132753A (en) 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
DE2546096C2 (en) * 1975-10-15 1983-08-25 Bayer Ag, 5090 Leverkusen Process for the preparation of 4-alkyl thiosemicarbazides
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
CH647676A5 (en) * 1978-12-22 1985-02-15 Donald E Panoz ORAL, PROGRAM RELEASED GALENIC FORMS AND METHODS OF PREPARING THE SAME.
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3024416C2 (en) * 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Process for the production of medicaments with sustained release of active substances
US4467378A (en) * 1980-11-19 1984-08-21 Staar S. A. Two step cassette return mechanism for cassette tape decks
US4539199A (en) 1981-01-14 1985-09-03 Egyt Gyogyszervegyeszeti Gyar Sustained release pharmaceutical compositions
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DE3208791A1 (en) * 1982-03-11 1983-09-22 Röhm GmbH, 6100 Darmstadt METHOD FOR COATING MEDICINAL PRODUCTS BY MEANS OF A COATING AGENT DISPERSED IN WATER
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4443428A (en) 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4557925A (en) 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
ZA836627B (en) 1982-10-08 1984-05-30 Verex Lab Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
EP0147780A3 (en) 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
DE3405378A1 (en) 1984-02-15 1985-08-22 Röhm GmbH, 6100 Darmstadt MEDICINE COVER
DE3565850D1 (en) * 1984-06-27 1988-12-01 Nitto Electric Ind Co Powdered coating composition of epoxy resin and filler
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4894234A (en) * 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for antiarrhythmics
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DE3686275T2 (en) 1985-01-11 1993-03-18 Teijin Ltd PREPARED PRODUCTS WITH DELAYED RELEASE.
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
GB2170104A (en) 1985-01-30 1986-07-30 Warner Lambert Co Coated pharmaceutical dosage forms
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
NL8500724A (en) * 1985-03-13 1986-10-01 Univ Groningen DEVICES FOR REGULAR RELEASE OF ACTIVE SUBSTANCES AND METHOD OF MANUFACTURE THEREOF
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
DE3687541T2 (en) * 1985-05-13 1993-05-13 Miles Inc USE OF CALCIUM ANTAGONISTS FOR THE PRODUCTION OF COMPOSITIONS FOR WITHDRAWAL SYMPTOMS.
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
EP0212747B1 (en) 1985-08-16 1991-04-10 The Procter & Gamble Company Drug particles having constant release and immediate release
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US4892742A (en) 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US4904476A (en) 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4863456A (en) 1986-04-30 1989-09-05 Alza Corporation Dosage form with improved delivery capability
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ES2058111T3 (en) * 1986-06-10 1994-11-01 Euro Celtique Sa COMPOSITION OF CONTROLLED RELEASE OF DIHYDROCODEIN.
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
IT1200178B (en) 1986-07-23 1989-01-05 Alfa Farmaceutici Spa GALENIC FORMULATIONS WITH SCHEDULED SALE CONTAINING DRUGS WITH ANTI-FLOGISTIC ACTIVITY
US4760094A (en) 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
IT1201136B (en) 1987-01-13 1989-01-27 Resa Farma TABLET FOR PHARMACEUTICAL USE SUITABLE FOR THE RELEASE OF SUBSTANCES OF ACTIVE SUBSTANCES
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4873092A (en) 1987-05-21 1989-10-10 Murata Kikai Kabushiki Kaisha Slow-releasing preparation
US5023088A (en) 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US5219575A (en) * 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
DE3721721C1 (en) * 1987-07-01 1988-06-09 Hoechst Ag Process for coating granules
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
SE8703881D0 (en) 1987-10-08 1987-10-08 Haessle Ab NEW PHARMACEUTICAL PREPARATION
US4844896A (en) 1987-11-02 1989-07-04 Lim Technology Laboratories, Inc. Microencapsulated insecticidal pathogens
US4948586A (en) 1987-11-02 1990-08-14 Lim Technology Laboratories, Inc. Microencapsulated insecticidal pathogens
US4971805A (en) 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
US5460817A (en) 1988-01-19 1995-10-24 Allied Colloids Ltd. Particulate composition comprising a core of matrix polymer with active ingredient distributed therein
EP0327295A3 (en) 1988-02-01 1989-09-06 F.H. FAULDING & CO. LTD. Tetracycline dosage form
US4861596A (en) * 1988-03-21 1989-08-29 Pfizer Inc. Rolled matrix device having enhanced ability to unroll and method for its production
DE3812567A1 (en) 1988-04-15 1989-10-26 Basf Ag METHOD FOR PRODUCING PHARMACEUTICAL MIXTURES
MC2025A1 (en) 1988-04-20 1990-04-25 Asta Pharma Ag MEDICINAL PRODUCT CONTAINING AZELASTINE AND CAPABLE OF RELEASING IT IN A CONTROLLED WAY
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
JP2681373B2 (en) * 1988-07-18 1997-11-26 塩野義製薬株式会社 Method for manufacturing sustained-release preparation
US4959219A (en) * 1988-08-15 1990-09-25 Fisons Corporation Coating barriers comprising ethyl cellulose
GB8820327D0 (en) 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
US4983730A (en) * 1988-09-02 1991-01-08 Hoechst Celanese Corporation Water soluble cellulose acetate composition having improved processability and tensile properties
ATE107854T1 (en) 1988-09-30 1994-07-15 Rhone Poulenc Rorer Ltd PHARMACEUTICAL GRANULES.
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
CA2007055A1 (en) 1989-01-06 1990-07-06 Garth Boehm Theophylline dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US4956182A (en) 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5326572A (en) 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5002774A (en) * 1989-06-08 1991-03-26 Erbamont, Inc. Sustained release pharmaceutical tablet
DK161743C (en) * 1989-07-03 1992-02-17 Niro Atomizer As PROCEDURE AND APPARATUS FOR AGGLOMERATION OF A POWDER-SHAPED MATERIAL
EP0415693A1 (en) 1989-08-28 1991-03-06 Arizona Technology Development Corporation Composition and method for selective enhancement of opiate activity and reduction of opiate tolerance and dependence
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
IL96311A (en) 1989-12-01 1995-05-26 Abbott Lab Sustained-release drug dosage units
US5258436A (en) * 1989-12-19 1993-11-02 Fmc Corporation Film-forming composition; method of producing same and use for coating pharmaceuticals and foods and the like
US5248516A (en) * 1989-12-19 1993-09-28 Fmc Corporation Film-forming composition: method of producing same and use for coating pharmaceuticals and foods and the like
JPH0674206B2 (en) 1989-12-28 1994-09-21 田辺製薬株式会社 Controlled release formulation and process for producing
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5158777A (en) 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5206030A (en) * 1990-02-26 1993-04-27 Fmc Corporation Film-forming composition and use for coating pharmaceuticals, foods and the like
DK0452145T3 (en) 1990-04-12 1996-12-02 Shionogi & Co Coated preparation and preparation thereof
JP2542122B2 (en) * 1990-04-18 1996-10-09 旭化成工業株式会社 Spherical nucleus, spherical granule and method for producing the same
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
JPH0481086A (en) 1990-07-20 1992-03-13 Mitsubishi Electric Corp Motion adaptive scanning line interpolating device
GB2253346A (en) 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
WO1992001446A1 (en) 1990-07-20 1992-02-06 Aps Research Limited Sustained-release formulations
FR2665357B1 (en) 1990-07-31 1995-03-31 Aiache Jean Marc PROCESS FOR THE PREPARATION OF A BIO-ADHESIVE GALENIC FORM AND GALENIC FORM THUS PREPARED.
ES2075403T3 (en) * 1990-08-24 1995-10-01 Spirig Ag Pharmazeutische Prap PROCEDURE FOR THE MANUFACTURE OF PELLETS.
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
SE9003296L (en) 1990-10-16 1992-04-17 Kabi Pharmacia Ab PROCEDURE SHOULD FORMULATE MEDICINAL PRODUCTS
SE9003665D0 (en) 1990-11-16 1990-11-16 Kabivitrum Ab MORPHINE PRODRUGS
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
US5403593A (en) 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
GB9104854D0 (en) 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5132142A (en) * 1991-03-19 1992-07-21 Glatt Gmbh Apparatus and method for producing pellets by layering power onto particles
ES2111065T5 (en) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited PROCEDURE TO PRODUCE A SOLID DISPERSION.
TW209174B (en) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
ES2073301T3 (en) * 1991-05-20 1995-08-01 Marion Laboratories Inc MULTI-LAYER COMPOSITION OF CONTROLLED RELEASE.
US5226902A (en) 1991-07-30 1993-07-13 University Of Utah Pulsatile drug delivery device using stimuli sensitive hydrogel
KR100221695B1 (en) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 Pharmaceutical spheroid formulation
HU217584B (en) 1991-09-06 2000-02-28 Mcneilab Inc. Pharmaceutical compositions containing at least one of the following compounds tramadole,- derivative and codeine, oxycodone or hydrocodone and process for producing them
DK0566709T5 (en) 1991-09-06 2009-05-18 Ortho Mcneil Janssen Pharm Composition containing a tramadol material and acetaminophen and use thereof
US5223541A (en) 1991-09-13 1993-06-29 Mcneilab, Inc. Tramadol n-oxide material, enantiomers and compositions thereof, and their use
DE69229881T2 (en) 1991-10-04 1999-12-09 Yoshitomi Pharmaceutical DELAYED RELEASE TABLET
GB9121204D0 (en) 1991-10-04 1991-11-20 Euro Celtique Sa Medicament
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
WO1993007859A1 (en) 1991-10-23 1993-04-29 Warner-Lambert Company Novel pharmaceutical pellets and process for their production
AU661723B2 (en) 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
DE4138513A1 (en) 1991-11-23 1993-05-27 Basf Ag SOLID PHARMACEUTICAL RETARD FORM
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5167964A (en) 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
US5262173A (en) 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
SE9200858L (en) 1992-03-20 1993-09-21 Kabi Pharmacia Ab Method for producing delayed release pellets
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
DE4220782A1 (en) 1992-06-25 1994-01-05 Basf Ag Process for the preparation of solid pharmaceutical sustained release forms
SE9202250D0 (en) 1992-07-29 1992-07-29 Gacell Lab Ab CONTROLLED RELEASE MORPHINE PREPARATION
ATE217188T1 (en) 1992-08-05 2002-05-15 Faulding F H & Co Ltd GRANULATED PHARMACEUTICAL COMPOSITION
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5330759A (en) 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
WO1994005262A1 (en) 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Sustained release matrix composition
US5386493A (en) * 1992-09-25 1995-01-31 Apple Computer, Inc. Apparatus and method for playing back audio at faster or slower rates without pitch distortion
EP0665010B1 (en) 1992-10-16 2002-09-11 Nippon Shinyaku Company, Limited Method of manufacturing wax matrices
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
IT1264020B (en) 1993-01-28 1996-09-09 Recordati Chem Pharm PROCEDURE FOR THE PREPARATION OF MICROGRANULES SUITABLE FOR SUSPENSION IN LIQUIDS
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5753261A (en) 1993-02-12 1998-05-19 Access Pharmaceuticals, Inc. Lipid-coated condensed-phase microparticle composition
US5820879A (en) 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
US5654006A (en) 1993-02-12 1997-08-05 Mayo Foundation For Medical Education And Research Condensed-phase microparticle composition and method
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
SE9301057L (en) 1993-03-30 1994-10-01 Pharmacia Ab Controlled release preparation
US5436011A (en) 1993-04-16 1995-07-25 Bristol-Myers Squibb Company Solid pharmaceutical dosage form and a method for reducing abrasion
ES2149250T3 (en) 1993-04-23 2000-11-01 Novartis Ag DEVICE FOR THE ADMINISTRATION OF MEDICINES WITH CONTROLLED RELEASE.
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
IL109944A (en) 1993-07-01 1998-12-06 Euro Celtique Sa Sustained release dosage unit forms containing morphine and a method of preparing these sustained release dosage unit forms
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4329794C2 (en) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadol salt-containing drugs with delayed release
US5380790A (en) 1993-09-09 1995-01-10 Eastman Chemical Company Process for the preparation of acrylic polymers for pharmaceutical coatings
EP0647448A1 (en) * 1993-10-07 1995-04-12 Euroceltique S.A. Orally administrable opioid formulations having extended duration of effect
AU4449399A (en) 1993-10-07 1999-10-14 Euro-Celtique S.A. Orally administrable opioid formulations having extended duration of effect
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
KR100354702B1 (en) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 Manufacturing method and sustained release composition of pharmaceutical composition
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5484608A (en) 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
DE4413350A1 (en) 1994-04-18 1995-10-19 Basf Ag Retard matrix pellets and process for their production
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5958458A (en) 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5529787A (en) 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US6491945B1 (en) * 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
JPH08157392A (en) 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd Release control type preparation
US5958551A (en) 1995-08-31 1999-09-28 Garcia-Ochoa; Jorge-Isaac Structural element
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5616707A (en) 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
IL139728A (en) 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
AU702801B2 (en) 1995-07-14 1999-03-04 Darwin Discovery Limited Therapeutic use of D-threo-methylphenidate
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
DE19526759A1 (en) 1995-07-21 1997-01-23 Wacker Chemie Gmbh Redispersible, crosslinkable dispersion powder
DE19529445A1 (en) 1995-08-10 1997-02-13 Basf Ag Use of polymers based on ethylene, (meth) acrylic acid esters and (meth) acrylic acid for coating or sealing laminated safety glass panes
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US5807579A (en) 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
SE9600046D0 (en) 1996-01-05 1996-01-05 Astra Ab New pharmaceutical formulation
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
AU2068797A (en) 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
US5783212A (en) 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
WO1997032093A1 (en) 1996-03-01 1997-09-04 Bhp Steel (Jla) Pty. Ltd. Insulation system
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
EA001773B1 (en) 1996-03-08 2001-08-27 Нюкомед Данмарк А/С Oral pharmaceutical medicament as modified release miltiple units composition
ES2168610T3 (en) * 1996-03-12 2002-06-16 Alza Corp COMPOSITION AND GALENIC FORM CONTAINING AN OPIOID ANTAGONIST.
JP3511042B2 (en) 1996-06-28 2004-03-29 ソニー株式会社 Steel plate for heat shrink band
US20020110595A1 (en) 1996-06-28 2002-08-15 Basf Corporation Slow release pharmaceutical compositions
DE19630035A1 (en) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol multiple unit formulations
TW477708B (en) 1996-09-13 2002-03-01 Shionogi & Amp Co Use of the thermal change to produce a substained release preparations and a process for their production
DK0932388T5 (en) 1996-09-30 2011-06-27 Alza Corp Dosage form and method of administration of drugs
FR2753904B1 (en) 1996-10-01 1998-10-30 Gattefosse Ets Sa PHARMACEUTICAL COMPOSITION WITH MODIFIED RELEASE OF ACTIVE SUBSTANCE, INCLUDING A MATRIX, AND MANUFACTURING PROCESS
US6375987B1 (en) 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
FR2754710B1 (en) 1996-10-22 1998-12-31 Prographarm Lab PROCESS FOR THE PREPARATION OF A MULTIPARTICULAR PHARMACEUTICAL FORM WITH CONTROLLED RELEASE PLURISEQUENTIELLE
DE19647692C2 (en) 1996-11-05 2002-06-20 Schuelke & Mayr Gmbh Washing disinfectant for hygienic and surgical hand disinfection
DE19653631A1 (en) 1996-12-20 1998-06-25 Basf Coatings Ag Process for producing radiation-crosslinkable polymeric acrylic or methacrylic acid esters
US5776856A (en) 1997-02-04 1998-07-07 Isp Investments Inc. Soluble polymer based matrix for chemically active water insoluble components
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
BE1011045A3 (en) 1997-03-14 1999-04-06 Ucb Sa Pharmaceutical composition for controlled release of active substances.
US5904927A (en) 1997-03-14 1999-05-18 Northeastern University Drug delivery using pH-sensitive semi-interpenetrating network hydrogels
AU732118B2 (en) 1997-04-01 2001-04-12 Cima Labs, Inc. Blister package and packaged tablet
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
GB9714675D0 (en) 1997-07-11 1997-09-17 Smithkline Beecham Plc Novel composition
US5851555A (en) 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
US5885616A (en) 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
EA002806B1 (en) 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaid)
RS49982B (en) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
KR100377916B1 (en) 1997-09-26 2003-03-29 와커-헤미 게엠베하 Method for producing polymers stabilised with protective colloids
US5843477A (en) 1997-09-30 1998-12-01 Bayer Corporation Lubricants for use in tabletting
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US20040028735A1 (en) 1997-11-14 2004-02-12 Unchalee Kositprapa Pharmaceutical formulation
PT1685839E (en) * 1997-12-22 2013-07-08 Euro Celtique Sa Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist
CA2314896C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
SE9704870D0 (en) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6156342A (en) 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
SE9803239D0 (en) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
UA67802C2 (en) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION
US20090149479A1 (en) 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US20080102121A1 (en) 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
US20060240105A1 (en) 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
JP4613275B2 (en) 1998-11-02 2011-01-12 エラン ファーマ インターナショナル，リミティド Multiparticulate modified release composition
US20080113025A1 (en) 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US7767708B2 (en) 1998-11-04 2010-08-03 Schering-Plough Animal Health Corp. Growth stimulant compositions
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
DE19901687B4 (en) 1999-01-18 2006-06-01 Grünenthal GmbH Opioid controlled release analgesics
PE20001396A1 (en) 1999-01-18 2000-12-23 Gruenenthal Chemie DELAYED MEDICINAL FORMULATIONS CONTAINING A COMBINATION OF AN OPIOID OR A PHYSIOLOGICALLY TOLERABLE SALT OF THE SAME, AN O-AGONIST
NZ513538A (en) 1999-02-03 2004-02-27 Powderject Res Ltd Pharmaceutical composition associated with hydrogel particles for administration by transdermal delivery from a needless syringe
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6680071B1 (en) 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
US6025502A (en) 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate
JP2002541093A (en) 1999-04-06 2002-12-03 ファーマクエスト・リミテッド Pharmaceutical dosage form for pulsed delivery of d-threo-methylphenidate and a second CNS stimulant
EA003907B1 (en) 1999-05-27 2003-10-30 Пфайзер Продактс Инк. Ziprasidone composition as suspension
ES2213949T3 (en) 1999-07-02 2004-09-01 Cognis Iberia, S.L. MICROCAPSULES I.
EP1064913B1 (en) 1999-07-02 2005-09-14 Cognis IP Management GmbH Microcaspules
DE19932603A1 (en) 1999-07-13 2001-01-25 Gruenenthal Gmbh Multi-layer film containing active substance made of in-situ cross-linked hydrophilic polymers
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
SE9903236D0 (en) 1999-09-10 1999-09-10 Astra Ab Method of obtaining microparticles
US6264983B1 (en) 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
US6262072B1 (en) * 1999-10-12 2001-07-17 Yung Shin Pharmaceutical Industrial Co. Ltd. Orally administered antimicrobial pharmaceutical formulations of ciprofloxacin
EP2269587A1 (en) * 1999-10-29 2011-01-05 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) * 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
DE60045695D1 (en) 1999-11-09 2011-04-14 Abbott Lab Hydromorphinonzusammensetzungen
HUP0204163A2 (en) 2000-02-08 2003-04-28 Euro-Celtique S.A. Controlled-release composition containing opioid agonist and antagonist and process for its preparation
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
AU2738302A (en) 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
UA81224C2 (en) 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
DE60216078T2 (en) 2001-05-11 2007-07-05 Endo Pharmaceuticals Inc. OPIOID CONTAINING ARZNEIFORM AGAINST MISUSE
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
CA2449519A1 (en) 2001-06-08 2002-12-19 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
JP4848101B2 (en) 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション Sustained release micropellet
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US20040052843A1 (en) 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
KR100540035B1 (en) 2002-02-01 2005-12-29 주식회사 태평양 Multi-stage oral drug controlled-release system
US7790215B2 (en) 2002-03-26 2010-09-07 Purdue Pharma Lp Sustained-release gel coated compositions
SI2425824T1 (en) 2002-04-05 2017-06-30 Mundipharma Medical Cee Gmbh Pharmaceutical preparation containing oxycodone and naloxone
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
CA2491572C (en) 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US20040208936A1 (en) 2002-07-22 2004-10-21 Roland Chorin Novel compositions
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040026812A1 (en) * 2002-08-12 2004-02-12 Tiy Inc. Apparatus for bench scale tablet-making
US20050266072A1 (en) 2002-08-15 2005-12-01 Euro-Celtique S.A. Pharmaceutical compositions
US20040052844A1 (en) 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
CA2498798A1 (en) 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
HUE038446T2 (en) 2002-09-20 2018-10-29 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
CA2499994C (en) 2002-09-23 2012-07-10 Verion, Inc. Abuse-resistant pharmaceutical compositions
US20060003004A1 (en) 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
WO2004045551A2 (en) 2002-11-15 2004-06-03 Branded Products For The Future Pharmaceutical composition
EP1589951B1 (en) 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
JP2006516969A (en) 2003-01-23 2006-07-13 アモレパシフィック コーポレーション Sustained release preparation and method for producing the same
US20040157784A1 (en) 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
DE602004024963D1 (en) 2003-03-13 2010-02-25 Controlled Chemicals Inc OXYCODON CONJUGATES WITH LOWER ABUSE POTENTIAL AND EXTENDED ACTIVITY
EP1782834A3 (en) 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
NZ542303A (en) 2003-03-14 2008-12-24 Nirmal Mulye A process for preparing sustained release tablets
SE0300831D0 (en) 2003-03-26 2003-03-26 Pharmacia Ab New formulations and use therof
ATE495732T1 (en) 2003-03-26 2011-02-15 Egalet As CONTROLLED RELEASE MORPHINE SYSTEM
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
CA2519556C (en) 2003-04-21 2011-01-18 Benjamin Oshlack Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
IN2003MU00504A (en) 2003-06-05 2005-05-13 Alembic Ltd
WO2005020929A2 (en) 2003-09-02 2005-03-10 Imran Ahmed Sustained release dosage forms of ziprasidone
US20050053656A1 (en) 2003-09-05 2005-03-10 Ping Jeffrey H. Compositions and methods for treating pain
US20090304793A1 (en) 2003-09-22 2009-12-10 Alpharma, Inc. Sustained release opioid formulations and methods of use
CA2540056C (en) 2003-09-26 2015-03-24 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
US20080031901A1 (en) 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
CA2541371C (en) 2003-10-03 2014-12-16 Atul M. Mehta Extended release formulations of opioids and method of use thereof
CN1874764B (en) 2003-10-10 2012-08-01 埃法尔姆公司 Sustained-release microgranules containing ginkgo extract and the process for manufacturing these
HUP0303382A2 (en) 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Pellets containing venlafaxin hydrochloride
EP1677798A2 (en) 2003-10-29 2006-07-12 Alza Corporation Once-a-day, oral, controlled-release, oxycodone dosage forms
DE602004031462D1 (en) 2003-12-31 2011-03-31 Cima Labs Inc GENERAL LINEAR SHELL FORM OF FENTANYL FOR ORAL USE AND METHOD OF ADMINISTRATION
US20050165038A1 (en) 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
GB0408308D0 (en) 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
US20060024361A1 (en) 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
EP1786404A2 (en) 2004-09-01 2007-05-23 Euro-Celtique S.A. Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax
US20070231268A1 (en) 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
MX2007012103A (en) 2005-04-13 2007-11-20 Pfizer Prod Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions.
US20060263429A1 (en) 2005-05-20 2006-11-23 Hengsheng Feng Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof
BRPI0612802A2 (en) 2005-07-07 2010-11-30 Farnam Co Inc sustained release pharmaceutical compositions for extremely water soluble drugs
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US20100172989A1 (en) 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US7584450B2 (en) * 2006-02-17 2009-09-01 Synopsys, Inc. Method and apparatus for using a database to quickly identify and correct a manufacturing problem area in a layout
ZA200807571B (en) 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
US20070212414A1 (en) 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
WO2007112574A1 (en) 2006-04-03 2007-10-11 Isa Odidi Extended release composition of venlafaxine
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
JP2010521494A (en) 2007-03-16 2010-06-24 エラン・ファルマ・インターナショナル・リミテッド Combination of narcotic and non-narcotic analgesics
WO2008117784A1 (en) 2007-03-26 2008-10-02 Nec Corporation Portable phone terminal, image display controlling method, program thereof, and program recording medium
WO2008140460A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20110065628A1 (en) 2007-08-27 2011-03-17 University Of Virginia Patent Foundation Medication Combinations for the Treatment of Alcoholism and Drug Addiction
EP2197448A4 (en) 2007-09-12 2010-11-17 Elan Pharma Int Ltd Dosing regimen
JP5204847B2 (en) 2007-09-21 2013-06-05 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング PH-dependent controlled release pharmaceutical opioid composition resistant to the effects of ethanol
ATE455538T1 (en) 2007-11-09 2010-02-15 Acino Pharma Ag SUSTAINED-RELEASE TABLETS WITH HYDROMORPHONE
JP2011511782A (en) 2008-02-12 2011-04-14 アボット・ラボラトリーズ Extended release hydrocodone acetaminophen and related methods and uses
US20100323016A1 (en) 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
MX340249B (en) 2008-08-15 2016-07-01 Depomed Inc Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders.
KR101660996B1 (en) 2008-09-16 2016-09-28 넥타르 테라퓨틱스 Pegylated opioids with low potential for abuse
US20130209560A1 (en) 2010-02-24 2013-08-15 Cima Labs Inc. Abuse-resistant formulations
EP2826468A1 (en) 2010-12-22 2015-01-21 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
HUE026981T2 (en) 2011-03-25 2016-08-29 Purdue Pharma Lp Controlled release pharmaceutical dosage forms
WO2013054285A1 (en) * 2011-10-11 2013-04-18 Ranbaxy Laboratories Limited A gastroretentive dosage system and process of preparation thereof
US20140161879A1 (en) 2012-07-31 2014-06-12 Zogenix, Inc. Treating pain in patients with hepatic impairment

Also Published As

Publication number Publication date
BR0015284A (en) 2004-08-03
ES2374717T3 (en) 2012-02-21
EP1623703B1 (en) 2011-10-05
HUP0203680A2 (en) 2003-03-28
JP2012036199A (en) 2012-02-23
IL149352A0 (en) 2002-11-10
JP2015131837A (en) 2015-07-23
EP2295043A1 (en) 2011-03-16
IL209703A0 (en) 2011-02-28
CN102716101A (en) 2012-10-10
JP6240279B2 (en) 2017-11-29
ATE526950T1 (en) 2011-10-15
CY1112260T1 (en) 2015-12-09
IL207613A (en) 2015-04-30
JP4806507B2 (en) 2011-11-02
HU230828B1 (en) 2018-08-28
KR20130010512A (en) 2013-01-28
EP1227798A4 (en) 2004-06-30
KR20120050528A (en) 2012-05-18
JP5536730B2 (en) 2014-07-02
RU2002113921A (en) 2004-01-10
JP5834052B2 (en) 2015-12-16
US9320717B2 (en) 2016-04-26
PT1623703E (en) 2012-01-09
KR20020059653A (en) 2002-07-13
CN1407884B (en) 2012-06-20
IL149352A (en) 2011-01-31
HK1054698A1 (en) 2003-12-12
RU2230556C2 (en) 2004-06-20
US8975273B2 (en) 2015-03-10
KR101216270B1 (en) 2012-12-31
KR101197919B1 (en) 2012-11-29
US20170136006A1 (en) 2017-05-18
WO2001032148A1 (en) 2001-05-10
US20150216810A1 (en) 2015-08-06
JP2017008089A (en) 2017-01-12
JP2007084568A (en) 2007-04-05
KR100889069B1 (en) 2009-03-17
US20170087153A1 (en) 2017-03-30
KR20130101157A (en) 2013-09-12
US20170143697A1 (en) 2017-05-25
EP1227798A1 (en) 2002-08-07
US8980291B2 (en) 2015-03-17
NO20022014L (en) 2002-06-20
US10076516B2 (en) 2018-09-18
EP2269587A1 (en) 2011-01-05
JP2013241461A (en) 2013-12-05
HK1087617A1 (en) 2006-10-20
IL207613A0 (en) 2010-12-30
AU764453B2 (en) 2003-08-21
NO333380B1 (en) 2013-05-21
US20150174121A1 (en) 2015-06-25
AU1446501A (en) 2001-05-14
AU2003262463B2 (en) 2005-06-16
EP1623703A1 (en) 2006-02-08
US9669022B2 (en) 2017-06-06
NO20022014D0 (en) 2002-04-26
NZ529928A (en) 2005-10-28
JP5184774B2 (en) 2013-04-17
US20110262532A1 (en) 2011-10-27
KR20100137025A (en) 2010-12-29
IL209703A (en) 2015-04-30
MXPA02004293A (en) 2002-10-31
US20150216809A1 (en) 2015-08-06
HUP0203680A3 (en) 2005-01-28
EP2305218A1 (en) 2011-04-06
US9278074B2 (en) 2016-03-08
AU2003262463A1 (en) 2003-12-18
KR20080015955A (en) 2008-02-20
BR0015284B1 (en) 2014-08-05
BRPI0015284B8 (en) 2021-05-25
US20190022086A1 (en) 2019-01-24
US20140377348A1 (en) 2014-12-25
JP6149058B2 (en) 2017-06-14
US20160228429A1 (en) 2016-08-11
US20040266807A1 (en) 2004-12-30
CA2389235C (en) 2007-07-17
CN1407884A (en) 2003-04-02
US7943174B2 (en) 2011-05-17
JP2003513032A (en) 2003-04-08
CN107213128A (en) 2017-09-29
KR101476574B1 (en) 2014-12-24
KR20050052544A (en) 2005-06-02
KR20110106471A (en) 2011-09-28
US9056107B1 (en) 2015-06-16
US9669024B2 (en) 2017-06-06
US20140112981A1 (en) 2014-04-24
CA2389235A1 (en) 2001-05-10
US9675611B1 (en) 2017-06-13

Similar Documents

Publication Publication Date Title
DK1623703T3 (en) Controlled release hydrocodone formulations
IL101162A (en) Pharmaceutical composition for oral administration comprising an indole derivative
DK383987D0 (en) NEW GALENIC FORMS WITH PROGRAMMED RELEASE CONTAINING ANTIPHLOGISTICS
ES2075338T3 (en) FORMULATION OF NAPROXENO, OF CONTROLLED ABSORPTION, FOR ADMINISTRATION ONCE A DAY.
CY1111088T1 (en) PHARMACEUTICAL FORM FOR TOLTERODIN ADMINISTRATION WITH CONTROLLED LIBERTY
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
CY1106763T1 (en) PREVENTIVE OR THERAPEUTIC MEANS FOR INFLAMMATORY BOWEL DISEASES
DK0754034T3 (en) Effervescent pharmaceutical formulations containing biodegradable controlled release microcapsules
BR9802537A (en) Method to anesthetize a human patient before single-dose surgery and pharmaceutical system for administration
ATE268174T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING SIBUTRAMIN AND ORLISTAT
GEP20063804B (en) Once-a-day oxycodone formulations
UA30143A (en) MEDICAL DRUG FOR PREVENTION AND TREATMENT OF INFECTIOUS AND INFLAMMATORY DISEASES